TriPath Imaging Ramps Up Regulatory And Clinical Spending In 2006
This article was originally published in The Gray Sheet
Executive Summary
TriPath Imaging will increase investment in its regulatory and clinical affairs programs by $6.5 mil.-$7 mil. in 2006 to support FDA approval of its breast cancer staging assay, SurePath molecular Pap test and FocalPoint GS imaging system
You may also be interested in...
TriPath Withdraws Its Second PMA Supplement Application This Year
TriPath Imaging has been reorganizing its clinical and regulatory affairs operations to prevent the continuation of problems that caused it to withdraw two separate PMA supplements so far this year
TriPath/Digene
TriPath will resubmit its withdrawn PMA supplement application to FDA "at the earliest possible date" for use of SurePath liquid-based Pap test specimen-collection medium samples with Digene's Hybrid Capture 2 (HC2) high-risk human papillomavirus (HPV) DNA test, the firm says. The withdrawal of the August 2004 application follows discussions with FDA that revealed "additional clinical information and analyses would be required," TriPath explains (1"The Gray Sheet" Aug. 30, 2004, In Brief). A Digene PMA supplement for the combination was rejected by FDA in 2002. TriPath reports it achieved profitability for the first time in 2004, earning $605,000 on sales of $68.5 mil., up 27%...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.